Abstract:Signal transducers and activators of transcription (STATs) are a family of transcription factors involved in the regulation of early embryonic development, immune response, cell proliferation, differentiation, and apoptosis. Particularly, STAT3 regulates lobuloalveolar apoptosis during involution in mammary gland development, and its activation is required for the growth of CD44+CD24- stem cell-like breast cancer cells and the development of multiple cancers including breast cancer. Increased STAT3 transcriptional activity was found to correlate with ER-negative phenotype in breast cancer cell lines and in primary human invasive ductal breast carcinomas. Thus, STAT3 represents a promising target for therapeutic and preventive intervention of breast cancer. Yet current strategies of inhibiting STAT3 activity did not sufficiently block STAT3 activation in cancer cells due to their limited potency, poor solubility or bioavailability. Despite several STAT3 inhibitors have been advanced into early clinical trials, there is an urgent need to develop a more successful strategy targeting STAT3 for cancer therapies, and preventive use in particular. We attempted to identify potent and orally active STAT3 inhibitors for such purposes and have designed, synthesized and screened a series of novel STAT3 inhibitors utilizing fragment-based drug design strategy. A number of small molecules with new scaffolds have been discovered with low-micromolar to nanomolar potency in inhibiting the proliferation of various human breast cancer and pancreatic cancer cells. The identified compound HJC0152 significantly suppresses basal and IL-6-stimulated STAT3 promoter activity and STAT3 phosphorylation, reduces total STAT3 protein expression, induces G2/M cell cycle arrest, and induces early apoptosis. HJC0152 has demonstrated a better potency in suppressing the growth of MDA-MB-231 breast xenograft tumors via intraperitoneal and oral administrative routes, with remarkably improved aqueous solubility (3,300 fold improvement) and less toxicity than the lead compounds. In conclusion, we have developed a new class of orally active STAT3 inhibitors with superior drug-like properties for further preclinical therapeutic and preventive evaluation. Citation Format: Zhengduo Yang, Haijun Chen, Lili Chu, Yusong Zhang, Chunyong Ding, Kristin Terry, Jia Zhou, Qiang Shen. Developing novel STAT3 inhibitors for the treatment and prevention of cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B63.

Targeted blockage of STAT3 pathway with JSI-124 inhibits the proliferation of H1975 cells of non-small-cell lung cancer

Physalin A Exerts Anti-Tumor Activity in Non-Small Cell Lung Cancer Cell Lines by Suppressing JAK/STAT3 Signaling.

Improving the drug susceptibility of gefitinib-resistant in non-small cell lung cancer by inhibiting the STAT3 activity

STAT1 Inhibits Human Hepatocellular Carcinoma Cell Growth Through Induction of P53 and Fbxw7

Effect of blocking STAT3 signaling pathway on growth of human pancreatic cancer cells

HJC0152, a Novel STAT3 Inhibitor with Promising Anti-Tumor Effect in Gastric Cancer

JSI-124 (Cucurbitacin I) inhibits tumor angiogenesis of human breast cancer through reduction of STAT3 phosphorylation.

siRNA against signal transducer and activator of transcription 3 inhibits proliferation of HepG2 cells in vitro

Effect of insulin like growth factor binding protein 3 on non-small cell lung cancer

Effects on the STAT3-shRNA in Non-Small-Cell Lung Cancer Therapy: Design, Induction of Apoptosis, and Conjugation with Chitosan-Based Gene Vectors

The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.

Effects of an Inhibitor of Signal Transducer and Activator of Transcription 3,WP 1066,on the Biological Characteristics of Hepatocellular Carcinoma

Abstract 3805: Anticancer Agent HJC0416 Inhibits the Growth of Breast Cancer Xenografts Via Downregulating STAT3 Signaling

[Effects of JAK2/STAT3 Signaling Pathway on Angiogenesis in Non-Small Cell Lung Cancer].

Abstract B63: Developing Novel STAT3 Inhibitors for the Treatment and Prevention of Cancer

Effect of Specific Inhibition of JAK/STAT3 Signaling Pathway on Hepatocellular Carcinoma in Rats

Therapeutic Effects of Stat3 Decoy Oligodeoxynucleotide on Human Lung Cancer in Xenograft Mice

Effect of Inhibiting STAT3 Gene on Growth of Human Pancreatic Cancer Cells in Vitro

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

A Novel Small Molecular STAT3 Inhibitor, 5Br-6B, Induces Apoptosis and Inhibits Migration in Colorectal Cancer Cells

A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in